Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 3/20 | 0.53 |
| ▸ | STS | P08842 | 5/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865007 | 0.91 | ALDH1A1 (0.54) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL4713688 | 0.90 | ALDH1A1 (0.53) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL4711912 | 0.88 | CNR1 (0.50) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL31282736 | 0.85 | ALDH1A1 (0.57) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL5121483 | 0.85 | ALDH1A1 (0.57) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL25390329 | 0.84 | USP30 (0.59) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL22521596 | 0.84 | ALDH1A1 (0.56) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL4717960 | 0.84 | NOS2 (0.52) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL6249997 | 0.84 | ALDH1A1 (0.56) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL4716931 | 0.83 | ALDH1A1 (0.57) | ALDH1A1HTTNPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| EP-1497285-B1 | BENZOXAZINONE-DERIVED COMPOUNDS, THEIR PREPARATION UND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2010-11-24 | — | — | EP | disclosed |
| EP-1648886-B1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2009-12-09 | — | — | EP | disclosed |
| EP-1660131-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2009-06-24 | — | — | EP | disclosed |
| US-7514429-B2 | Benzoxazinone-derived compounds, their preparation and use as medicaments | ESTEVE LABORATORIOS DR. ESTEVE S.A. (ES) | 2009-04-07 | — | — | US | disclosed |
| US-7514429-B2 | Benzoxazinone-derived compounds, their preparation and use as medicaments | ESTEVE LABORATORIOS DR. ESTEVE S.A. (ES) | 2009-04-07 | — | — | US | disclosed |
| US-7514429-B2 | Benzoxazinone-derived compounds, their preparation and use as medicaments | ESTEVE LABORATORIOS DR. ESTEVE S.A. (ES) | 2009-04-07 | — | — | US | disclosed |
| EP-1648468-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2008-09-24 | — | — | EP | disclosed |
| US-7056914-B2 | Benzoxazinone-derived compounds, their preparation and use as medicaments | ESTEVE LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-06-06 | — | — | US | disclosed |
| US-7041665-B2 | Benzoxazinone derivatives, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2006-05-09 | — | — | US | disclosed |
| EP-1648468-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| EP-1500654-B1 | BENZOXAZINONE DERIVATIVES, THE PREPARATION AND USE THEREOF AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005014000-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| EP-1500654-A1 | BENZOXAZINONE DERIVATIVES, THE PREPARATION AND USE THEREOF AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-01-26 | — | — | EP | disclosed |
| EP-1497285-A1 | BENZOXAZINONE-DERIVED COMPOUNDS, THEIR PREPARATION UND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-01-19 | — | — | EP | disclosed |
| US-20040067941-A1 | Benzoxazinone derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-04-08 | — | — | US | disclosed |
| US-20040058920-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2004-03-25 | — | — | US | disclosed |
| WO-2003084952-A1 | BENZOXAZINONE-DERIVED COMPOUNDS, THEIR PREPARATION UND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058920-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | XDH, CYP3A5, CYP4X1 | ALDH1A1 510/4885HTT 3417/4885NPC1 1947/4885 |
| US-20040067941-A1 | Benzoxazinone derivatives, their preparation and use as medicaments | XDH, CYP4X1, CYP3A5 | ALDH1A1 369/4885HTT 2041/4885NPC1 959/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | ALDH1A1 3499/4885HTT 1224/4885NPC1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.